SAB Biotherapeutics moved its corporate headquarters to Miami Beach ahead of a receiving clearance to begin a clinical trial for a new type 1 diabetes treatment.
Previously based in Sioux Falls, South Dakota, the company now has a 1,300-square-foot headquarters office at 777 W 41st St. (777 Arthur Godfrey Road) that opened in April. The firm’s research and development campus remains in South Dakota.
Chairman and CEO Samuel J. Reich is a longtime Miami resident.
Source: SFBJ